The Life Sciences team advised Relay Therapeutics, Inc. in its exclusive global license agreement with Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., to develop and commercialize lirafugratinib (RLY-4008), a selective small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. Under the terms of the agreement, Elevar Therapeutics will assume full responsibility with respect to lirafugratinib for all further development activities, including submission of the NDAs, all subsequent clinical development, and global commercialization for FGFR2-driven CCA and FGFR2-altered other solid tumors. In consideration for the license grant, Relay Therapeutics is eligible to receive up to $75 million in upfront and regulatory milestones, plus up to $425 million in potential commercial milestone payments and tiered royalties up to the low-teens percentage.
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.
The Goodwin team was led by Kathleen Kean and Frank Qin, with invaluable assistance from Dan Karelitz and Julie Tibbets.
For additional details on the agreement, please read the press release.
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.
The Goodwin team was led by Kathleen Kean and Frank Qin, with invaluable assistance from Dan Karelitz and Julie Tibbets.
For additional details on the agreement, please read the press release.